Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit?

Mirco Pistelli¹, Zelmira Ballatore^1*, Mariagrazia De Lisa¹, Miriam Caramanti¹, Alessandra Pagliacci¹, Nicola Battelli¹, Francesca Ridolfi¹, Alfredo Santinelli², Tommasina Biscotti², Rossana Berardi¹ and Stefano Cascinu¹

¹Clinical of Medical Oncology, Marche Polytechnic University, AO Riuniti Hospital -Ancona, Italy

²Department of Pathology, Marche Polytechnic University, AO Riuniti Hospital-Ancona, Italy

^*Corresponding Author: Zelmira Ballatore, Clinical of Medical Oncology, Marche Polytechnic University, AO Riuniti Hospital -Ancona, Italy, Tel: +39 3381240196 Email: